Margret Leosdottir on Statin–Ezetimibe Algorithm Dramatically Improving Post-MI LDL-C Outcomes
Margret Leosdottir, Senior cardiology consultant at Skane University Hospital, shared on LinkedIn:
”At Skåne University Hospital in Malmö, in November 2022 we launched an algorithm to support our CCU doctors to prescribe lipid-lowering therapy during ACS hospitalization, focused on increasing the use of ezetimibe for patients not expected to reach goal on high-dose atorvastatin alone.
The algorithm was inspired by prior work from France under the lead of Prof François Schiele.
In just a couple of months, at our hospital the proportion of patients reaching LDL-C goal at 2-months post-MI increased from 30% to 55%.
This increase has remained since, with approximately 65% of our patients now at goal at one-year post-MI
Today we launch a new version of the algorithm, switching primary choice of high-intensity statin to rosuvastatin and further adapting recommendations to the 2025 European Society of Cardiology and European Atherosclerosis Society Lipid GL update.
Failure to implement evidence-based medicine is a major cause of concern in today´s healthcare.
Often simple measures like these can carry us a long way, improving prognosis for our patients and making better use of limited healthcare resources.
The example also shows the usefulness of national registries like SWEDEHEART to track progress and benchmark quality improvement efforts at your clinic
With Emil Hagström and Jessica Schubert.”
Stay updated with Hemostasis Today.
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
-
Apr 14, 2026, 16:56Saskia Middeldorp: Key Takeaways from the 2026 ACC/AHA Guideline on Acute PE
-
Apr 14, 2026, 16:54Chokri Ben Lamine: Extracorporeal Photopheresis for aGVHD cGVHD Post-SCT – 50 Pearls
-
Apr 14, 2026, 16:49Ahmed Magdi Omar: Key Takeaways From the Latest 2026 Guidelines on Antiplatelet Therapy in AIS